These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

880 related items for PubMed ID: 21981682

  • 1. Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study.
    Egerdie RB, Auerbach S, Roehrborn CG, Costa P, Garza MS, Esler AL, Wong DG, Secrest RJ.
    J Sex Med; 2012 Jan; 9(1):271-81. PubMed ID: 21981682
    [Abstract] [Full Text] [Related]

  • 2. Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia and on erectile dysfunction in sexually active men with both conditions: analyses of pooled data from four randomized, placebo-controlled tadalafil clinical studies.
    Porst H, Roehrborn CG, Secrest RJ, Esler A, Viktrup L.
    J Sex Med; 2013 Aug; 10(8):2044-52. PubMed ID: 23782459
    [Abstract] [Full Text] [Related]

  • 3. Tadalafil once daily improves ejaculatory function, erectile function, and sexual satisfaction in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia and erectile dysfunction: results from a randomized, placebo- and tamsulosin-controlled, 12-week double-blind study.
    Giuliano F, Oelke M, Jungwirth A, Hatzimouratidis K, Watts S, Cox D, Viktrup L.
    J Sex Med; 2013 Mar; 10(3):857-65. PubMed ID: 23346990
    [Abstract] [Full Text] [Related]

  • 4. Tadalafil once daily in the treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) in men without erectile dysfunction.
    Brock G, Broderick G, Roehrborn CG, Xu L, Wong D, Viktrup L.
    BJU Int; 2013 Nov; 112(7):990-7. PubMed ID: 23937669
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial.
    Porst H, Kim ED, Casabé AR, Mirone V, Secrest RJ, Xu L, Sundin DP, Viktrup L, LVHJ study team.
    Eur Urol; 2011 Nov; 60(5):1105-13. PubMed ID: 21871706
    [Abstract] [Full Text] [Related]

  • 6. Sexual function in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: results of a 6-month, randomized, double-blind, placebo-controlled study of tadalafil coadministered with finasteride.
    Glina S, Roehrborn CG, Esen A, Plekhanov A, Sorsaburu S, Henneges C, Büttner H, Viktrup L.
    J Sex Med; 2015 Jan; 12(1):129-38. PubMed ID: 25353053
    [Abstract] [Full Text] [Related]

  • 7. Effectiveness of tadalafil 5 mg once daily in the treatment of men with lower urinary tract symptoms suggestive to benign prostatic hyperplasia with or without erectile dysfunction: results from naturalistic observational TadaLutsEd study.
    Bechara A, Casabe A, Rodriguez Baigorri G, Cobreros C.
    J Sex Med; 2014 Feb; 11(2):498-505. PubMed ID: 24224728
    [Abstract] [Full Text] [Related]

  • 8. Tadalafil - a therapeutic option in the management of BPH-LUTS.
    Carson CC, Rosenberg M, Kissel J, Wong DG.
    Int J Clin Pract; 2014 Jan; 68(1):94-103. PubMed ID: 24341303
    [Abstract] [Full Text] [Related]

  • 9. Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia in men with or without erectile dysfunction.
    Broderick GA, Brock GB, Roehrborn CG, Watts SD, Elion-Mboussa A, Viktrup L.
    Urology; 2010 Jun; 75(6):1452-8. PubMed ID: 20163842
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and Safety of a Fixed-Dose Combination Therapy of Tamsulosin and Tadalafil for Patients With Lower Urinary Tract Symptoms and Erectile Dysfunction: Results of a Randomized, Double-Blinded, Active-Controlled Trial.
    Kim SW, Park NC, Lee SW, Yang DY, Park JK, Moon DG, Yang SK, Lee SW, Moon KH, Ahn TY, Kim SW, Park K, Min KS, Ryu JK, Son H, Jung J, Hyun JS.
    J Sex Med; 2017 Aug; 14(8):1018-1027. PubMed ID: 28760246
    [Abstract] [Full Text] [Related]

  • 11. Direct effects of tadalafil on lower urinary tract symptoms versus indirect effects mediated through erectile dysfunction symptom improvement: integrated data analyses from 4 placebo controlled clinical studies.
    Brock GB, McVary KT, Roehrborn CG, Watts S, Ni X, Viktrup L, Wong DG, Donatucci C.
    J Urol; 2014 Feb; 191(2):405-11. PubMed ID: 24096120
    [Abstract] [Full Text] [Related]

  • 12. Comparative efficacy assessment of tamsulosin vs. tamsulosin plus tadalafil in the treatment of LUTS/BPH. Pilot study.
    Bechara A, Romano S, Casabé A, Haime S, Dedola P, Hernández C, Rey H.
    J Sex Med; 2008 Sep; 5(9):2170-8. PubMed ID: 18638006
    [Abstract] [Full Text] [Related]

  • 13. Erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH) combined responders to tadalafil after 12 weeks of treatment.
    Roehrborn CG, Egan KB, Miner MM, Ni X, Wong DG, Rosen RC.
    BJU Int; 2016 Jul; 118(1):153-60. PubMed ID: 26765325
    [Abstract] [Full Text] [Related]

  • 14. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study.
    Roehrborn CG, McVary KT, Elion-Mboussa A, Viktrup L.
    J Urol; 2008 Oct; 180(4):1228-34. PubMed ID: 18722631
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia.
    Casabé A, Roehrborn CG, Da Pozzo LF, Zepeda S, Henderson RJ, Sorsaburu S, Henneges C, Wong DG, Viktrup L.
    J Urol; 2014 Mar; 191(3):727-33. PubMed ID: 24096118
    [Abstract] [Full Text] [Related]

  • 16. Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial.
    Oelke M, Giuliano F, Mirone V, Xu L, Cox D, Viktrup L.
    Eur Urol; 2012 May; 61(5):917-25. PubMed ID: 22297243
    [Abstract] [Full Text] [Related]

  • 17. Changes in peak urinary flow and voiding efficiency in men with signs and symptoms of benign prostatic hyperplasia during once daily tadalafil treatment.
    Roehrborn CG, Kaminetsky JC, Auerbach SM, Montelongo RM, Elion-Mboussa A, Viktrup L.
    BJU Int; 2010 Feb; 105(4):502-7. PubMed ID: 19732051
    [Abstract] [Full Text] [Related]

  • 18. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia.
    McVary KT, Roehrborn CG, Kaminetsky JC, Auerbach SM, Wachs B, Young JM, Esler A, Sides GD, Denes BS.
    J Urol; 2007 Apr; 177(4):1401-7. PubMed ID: 17382741
    [Abstract] [Full Text] [Related]

  • 19. A comparative randomized prospective study to evaluate efficacy and safety of combination of tamsulosin and tadalafil vs. tamsulosin or tadalafil alone in patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
    Singh DV, Mete UK, Mandal AK, Singh SK.
    J Sex Med; 2014 Jan; 11(1):187-96. PubMed ID: 24165272
    [Abstract] [Full Text] [Related]

  • 20. Tadalafil once daily in men with erectile dysfunction: an integrated analysis of data obtained from 1913 patients from six randomized, double-blind, placebo-controlled, clinical studies.
    Porst H, Gacci M, Büttner H, Henneges C, Boess F.
    Eur Urol; 2014 Feb; 65(2):455-64. PubMed ID: 24119319
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 44.